Why the study?
Targeting Yes-associated protein may be a cancer therapy strategy, but the anticancer pharmacological mechanism of Licochalcone A had not been investigated in cholangiocarcinoma.
Licochalcone A demonstrates anticancer effects in cholangiocarcinoma cells by inhibiting the Hippo pathway via PES1 downregulation.
Answers are grounded in this paper and cite their sources.
LicA inhibits cholangiocarcinoma cell growth via Hippo inactivation in vitro; leaves open clinical translation pending in vivo studies.
Overexpression or activation of Yes-associated protein (YAP) is common in cancer cells. Thus, targeting YAP may be a strategy for cancer therapy. Licochalcone A (LicA) is a primary active compound of licorice root and is known to have medicinal effects, such as antioxidant, antibacterial, antiviral, and anticancer effects. However, the anticancer pharmacological mechanism of LicA has not been investigated in cholangiocarcinoma. In this study, we investigated the antiproliferative effect of LicA and the underlying molecular mechanism in HCCC-9810 and RBE human cholangiocarcinoma cells. Our experiments indicated that LicA suppressed the growth of cholangiocarcinoma cells through inactivation of the Hippo pathway. Pescadillo ribosomal biogenesis factor 1 (PES1) was notably upregulated and related to carcinogenesis. We also found that LicA suppressed the expression and nuclear localization of PES1, which was associated with the inhibition of YAP expression and transcriptional activity.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: